Driving Global Cancer Innovation
Through Translational Research

The Global Precision Medicine (GPM) group is a unique translational research collaboration between HI-STEM, DKFZ, and Genavinta. GPM combines multi-omics, AI, and clinical innovation, driving Genavinta’s mission to develop novel cancer technologies and solutions.

Our Research Focus Areas

Multi-Omics Integration for Holistic Cancer Understanding

We combine genomic, transcriptomic, and proteomic data with clinical outcomes to build comprehensive cancer profiles. This integrative approach enables the discovery of novel biomarkers and therapeutic targets, advancing personalized treatment strategies.

Global Collaboration for Inclusive Cancer Research

GPM partners with Genavinta to focus on underrepresented populations ensuring tomorrow's research addresses the true genetic diversity. Together, we foster collaborations that generate globally relevant intellectual property, high-impact publications, and biomarker-driven clinical trial.

AI-Driven Data Analysis for Rapid Translational Insights

Harnessing artificial intelligence and machine learning, GPM processes vast datasets to uncover actionable insights quickly and accurately. This accelerates the path from discovery to clinical application, a synergy that powers Genavinta’s scalable precision oncology solutions.